A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,036,645 shares of CABA stock, worth $6.95 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
3,036,645
Previous 3,036,645 -0.0%
Holding current value
$6.95 Million
Previous $22.7 Million 36.9%
% of portfolio
0.03%
Previous 0.04%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$16.79 - $25.38 $3.86 Million - $5.84 Million
-230,000 Reduced 7.04%
3,036,645 $51.8 Million
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $5.55 Million - $10.1 Million
725,000 Added 28.52%
3,266,645 $42.2 Million
Q4 2021

Feb 14, 2022

SELL
$3.36 - $14.64 $1.68 Million - $7.32 Million
-500,000 Reduced 16.44%
2,541,645 $9.63 Million
Q1 2021

May 17, 2021

SELL
$10.39 - $14.53 $1.45 Million - $2.02 Million
-139,160 Reduced 4.37%
3,041,645 $33.8 Million
Q4 2020

Feb 16, 2021

SELL
$9.81 - $15.8 $2.2 Million - $3.54 Million
-223,955 Reduced 6.58%
3,180,805 $39.7 Million
Q3 2020

Nov 16, 2020

SELL
$9.71 - $14.41 $1.56 Million - $2.31 Million
-160,249 Reduced 4.5%
3,404,760 $36.9 Million
Q2 2020

Aug 14, 2020

SELL
$6.39 - $11.28 $254,008 - $448,391
-39,751 Reduced 1.1%
3,565,009 $39.7 Million
Q1 2020

May 15, 2020

SELL
$6.0 - $18.67 $822,996 - $2.56 Million
-137,166 Reduced 3.67%
3,604,760 $26.3 Million
Q4 2019

Feb 14, 2020

BUY
$7.88 - $17.71 $29.5 Million - $66.3 Million
3,741,926 New
3,741,926 $52.3 Million

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $66.4M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.